[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liposomal-amphotericin-b\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liposomal-amphotericin-b":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100574065",false,"NCT06754436","Population Pharmacokinetics of L-AmB in Chinese Patients Assisted by Extracorporeal Membrane Pulmonary Oxygenation (ECMO)","Inclusion Criteria:\n\n* Diagnostic criteria for invasive fungal infections presenting to the intensive care unit (ICU) with probable or proved patients According to the 2021 EORTC\u002FMSGERC guideline.\n* Requiring ECOM assistance.\n* Age 18 years.\n\nExclusion Criteria:\n\n* Intolerance of L-AmB therapy.\n* Pregnancy.\n* Expected survival time \\\u003C24 hours.\n* Lack of necessary data on patient demographics physiopathology, and clinical status.","ALL","18 Years",{"count":17,"type":18},30,"ESTIMATED","INTERVENTIONAL",[21],"PHASE4","The goal of this study is to investigate the effects of ECMO-assisted therapy on L-AmB PK parameters in patients with critically ill patients of invasive fungal infections, and to determine the in vivo pharmacokinetic changes of L-AmB in the ECMO population. To establish and validate a population pharmacokinetic model for liposomal amphotericin B in patients with critically ill patients of invasive fungal infections treated with ECMO adjuvant therapy, and to explore the pharmacokinetics\u002Fpharmacodynamics of the drug with different dosing regimens.",[24,25],"Invasive Fungal Infections","Liposomal Amphotericin B","NOT_YET_RECRUITING","2024-12-30",{"date":29,"type":30},"2024-12-31","ACTUAL",{"date":32,"type":18},"2025-01-10",{"date":34,"type":18},"2026-02-01",{"name":36,"class":37},"Beijing Anzhen Hospital","OTHER",1,{"id":40,"slug":4,"hasResults":10,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":44,"targetDuration":46,"studyType":47,"phases":4,"briefSummary":48,"conditions":49,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":38},"100326406","NCT03529617","Pharmacokinetics of Liposomal Amphotericin B in Critically Ill vs. Non-critically Ill Hematological Patients: Exploration of Covariates","Inclusion Criteria:\n\n* Treatment with L-AmB\n* Admitted to an ICU or Hematology ward\n\nExclusion Criteria:\n\n* DNR 2 or 3\n* Pregnant or lactating women\n* Previous documentation of intolerance\u002Fsensitivity to L-AmB",{"count":45,"type":18},60,"1 Month","OBSERVATIONAL","This prospective study will compare the pharmacokinetic exposure to liposomal amphotericin B between critically ill patients and non-critically ill (hematology) patients in an early and late exposure day.",[50,25,51],"Pharmacokinetics","Critically Ill Patients","RECRUITING","2024-07-02",{"date":55,"type":30},"2024-07-03",{"date":57,"type":30},"2016-10-19",{"date":59,"type":18},"2025-12-31",{"name":61,"class":37},"Universitaire Ziekenhuizen KU Leuven",""]